Effect of Calcium Channel Blockers on Transmural Dispersion of Repolarization
Yes, there are studies demonstrating that calcium channel blockers, particularly verapamil, have minimal to no effect on transmural dispersion of repolarization (TDR), and this property may actually contribute to their low arrhythmogenic risk despite QT prolongation.
Key Evidence on CCBs and TDR
Verapamil's Unique Profile
The most compelling evidence comes from mechanistic studies showing that verapamil, despite being a potent IKr blocker, has never been associated with torsade de pointes (TdP) because it is a much more potent blocker of L-type calcium channels 1. This dual mechanism appears to prevent the development of increased TDR that would otherwise predispose to arrhythmias.
In a direct experimental study using an isolated rabbit heart model of long QT syndrome:
- Verapamil at therapeutic concentrations (0.01-0.05 µmol/L) had no effect on quinidine-induced changes in TDR 2
- This occurred despite quinidine significantly increasing TDR in a reverse rate-dependent fashion
- The calcium channel blockade did not modify the repolarization heterogeneity across ventricular layers
Mechanism Behind Low Arrhythmic Risk
The protective mechanism appears to involve:
Uniform repolarization delay across all myocardial layers rather than selective prolongation in M cells 1. Unlike high-risk drugs that selectively prolong repolarization in mid-myocardial cells, calcium channel blockers like verapamil uniformly delay repolarization across epicardium, mid-myocardium, and endocardium. This results in QT prolongation without creating the transmural heterogeneity necessary for reentrant arrhythmias.
Differential Effects Among CCB Classes
Research comparing different calcium channel blockers reveals important distinctions 3:
Dihydropyridines (DHPs) show variable effects:
- Nicardipine and amlodipine inhibited both IKr and IKs channels, which could compensate for action potential shortening from ICa blockade
- Isradipine shortened action potential duration more significantly and had only partial inhibitory effects on repolarizing currents (<50% at 30 µM)
- All three DHPs had similar potency on calcium channel blocking (IC50 values: 0.142-0.229 nM)
The key difference: Non-dihydropyridines (like verapamil) appear to have more balanced effects on multiple ion channels, preventing the development of increased TDR.
Clinical Implications from Guidelines
The 2017 AHA/ACC/HRS guidelines support the clinical safety of calcium channel blockers, recommending beta blockers or calcium channel blockers as useful therapy for symptomatic outflow tract ventricular tachycardia in otherwise normal hearts 4. This recommendation would not exist if these agents significantly increased TDR or arrhythmic risk.
Important Caveats
- Most direct TDR studies focus on verapamil specifically; data on other CCBs is more limited
- The protective effect appears related to multi-channel blockade rather than calcium channel blockade alone
- Experimental models suggest that L-type calcium channel blockade may actually reduce TdP risk 5, which aligns with the clinical safety profile of these agents
The evidence consistently demonstrates that calcium channel blockers, particularly non-dihydropyridines like verapamil, do not increase TDR and may represent a safer option than selective ion channel blockers when QT prolongation occurs.